vs

Side-by-side financial comparison of Granite Point Mortgage Trust Inc. (GPMT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $29.1M, roughly 1.3× Granite Point Mortgage Trust Inc.). On growth, Granite Point Mortgage Trust Inc. posted the faster year-over-year revenue change (-24.9% vs -57.1%). Over the past eight quarters, Granite Point Mortgage Trust Inc.'s revenue compounded faster (52.3% CAGR vs -46.5%).

Granite Point Mortgage Trust Inc. is a U.S.-based real estate finance company that primarily originates, manages and invests in senior secured commercial real estate debt instruments. Its core portfolio covers loans backed by multifamily, office, industrial, retail and other commercial property types across key U.S. regional markets, serving institutional and commercial real estate operator clients.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

GPMT vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.3× larger
ORGO
$37.2M
$29.1M
GPMT
Growing faster (revenue YoY)
GPMT
GPMT
+32.1% gap
GPMT
-24.9%
-57.1%
ORGO
Faster 2-yr revenue CAGR
GPMT
GPMT
Annualised
GPMT
52.3%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
GPMT
GPMT
ORGO
ORGO
Revenue
$29.1M
$37.2M
Net Profit
$-23.8M
Gross Margin
30.8%
Operating Margin
-81.9%
-185.1%
Net Margin
-81.9%
Revenue YoY
-24.9%
-57.1%
Net Profit YoY
38.7%
EPS (diluted)
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPMT
GPMT
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$29.1M
$225.6M
Q3 25
$33.7M
$150.9M
Q2 25
$33.8M
$101.0M
Q1 25
$35.1M
$86.7M
Q4 24
$38.7M
$126.7M
Q3 24
$44.3M
$115.2M
Q2 24
$48.5M
$130.2M
Net Profit
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
$-23.8M
$43.7M
Q3 25
$3.0M
$21.6M
Q2 25
$-13.4M
$-9.4M
Q1 25
$-7.0M
$-18.8M
Q4 24
$-38.8M
$7.7M
Q3 24
$-31.0M
$12.3M
Q2 24
$-63.1M
$-17.0M
Gross Margin
GPMT
GPMT
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
GPMT
GPMT
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-81.9%
28.1%
Q3 25
9.2%
13.7%
Q2 25
-39.5%
-12.5%
Q1 25
-19.8%
-30.9%
Q4 24
-100.3%
8.1%
Q3 24
-70.0%
5.4%
Q2 24
-130.1%
-10.7%
Net Margin
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
-81.9%
19.4%
Q3 25
9.0%
14.3%
Q2 25
-39.5%
-9.3%
Q1 25
-20.0%
-21.7%
Q4 24
-100.3%
6.1%
Q3 24
-70.0%
10.7%
Q2 24
-130.1%
-13.1%
EPS (diluted)
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
$-0.58
$0.31
Q3 25
$-0.01
$0.11
Q2 25
$-0.35
$-0.10
Q1 25
$-0.22
$-0.17
Q4 24
$-0.86
$0.05
Q3 24
$-0.69
$0.09
Q2 24
$-1.31
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPMT
GPMT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$66.0M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$552.7M
Total Assets
$1.8B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPMT
GPMT
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$66.0M
$93.7M
Q3 25
$62.7M
$63.7M
Q2 25
$85.1M
$73.1M
Q1 25
$85.7M
$110.0M
Q4 24
$87.8M
$135.6M
Q3 24
$113.5M
$94.3M
Q2 24
$85.9M
$89.9M
Total Debt
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
$552.7M
$300.1M
Q3 25
$582.0M
$255.1M
Q2 25
$584.2M
$233.2M
Q1 25
$604.7M
$242.9M
Q4 24
$619.1M
$262.9M
Q3 24
$667.8M
$278.5M
Q2 24
$704.6M
$263.5M
Total Assets
GPMT
GPMT
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$1.8B
$598.7M
Q3 25
$1.8B
$509.8M
Q2 25
$1.9B
$461.1M
Q1 25
$2.0B
$467.4M
Q4 24
$2.1B
$497.9M
Q3 24
$2.3B
$446.3M
Q2 24
$2.5B
$443.2M
Debt / Equity
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPMT
GPMT
ORGO
ORGO
Operating Cash FlowLast quarter
$2.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
$2.7M
$39.4M
Q3 25
$4.5M
$3.1M
Q2 25
$736.0K
$-32.9M
Q1 25
$-5.7M
$-19.9M
Q4 24
$8.8M
$10.9M
Q3 24
$6.1M
$8.7M
Q2 24
$987.0K
$4.7M
Free Cash Flow
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
GPMT
GPMT
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
1.49×
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons